Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL by Li, Xiaoyu et al.
Article
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 208 No. 4  663-675
www.jem.org/cgi/doi/10.1084/jem.20102384
663
NOTCH1 is a transcriptional activator with an 
essential role in the formation of numerous 
cancers. In human T cell acute lymphoblastic 
leukemia (T-ALL), NOTCH1 is frequently ac-
tivated by mutation and contributes to molec-
ular  pathogenesis  as  a  dominant  oncogene. 
Several essential pathways of NOTCH1-driven 
oncogenesis have been described. The human 
NOTCH1 gene was originally cloned in T-ALL 
at the breakpoint of the t(7;9) chromosomal 
translocation, which places the NOTCH1 gene 
under the control of the TCR gene promoter 
(Ellisen et al., 1991). Although this transloca-
tion occurs in only a small percentage of primary 
T-ALL,  activating  mutations  in  the  NOTCH1 
gene have been identified in >50% of patients 
with this disease (Weng et al., 2004). Several 
other alterations that result in increased intra-
cellular Notch1 (ICN1) levels after proteolytic 
cleavage have also been identified (Pece et al., 
2004; O’Neil et al., 2007). MYC has been iden-
tified as a critical direct downstream target gene 
of NOTCH1 in leukemogenesis (Palomero et al., 
2006; Sharma et al., 2006; Weng et al., 2006), 
but mouse  T-ALL studies suggest that NOTCH1 
has additional unidentified targets in transfor-
mation (Girard et al., 1996). In addition, numer-
ous tumor suppressors and oncogenes have been 
identified that cooperate with NOTCH1 in 
multiple distinct pathways, leading to transfor-
mation in human T-ALL. Undoubtedly, many 
more examples of cooperating mutations will 
be discovered (Armstrong and Look, 2005).
For our studies, we capitalized on a widely 
used mouse model of T-ALL (Pear et al., 1996) 
to search for molecular mechanisms downstream 
of activated Notch1. ICN1 overexpression in 
mouse hematopoietic precursor cells results in 
T-ALL characterized by extensively dysregulated 
gene expression in the face of genomic stability 
(Li et al., 2008). In this model, Lin-negative 
BM cells are retrovirally transduced with ICN1 
before transfer into -irradiated recipients (Pear 
et al., 1996). ICN1 overexpression first gener-
ates  nontumorigenic  CD4+CD8+ TCR+ 
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The NOTCH1 signaling pathway is a critical determinant of cell fate decisions and drives 
oncogenesis through mechanisms that are incompletely understood. Using an established 
mouse model of T cell acute lymphoblastic leukemia (T-ALL), here we report that induction 
of intracellular Notch1 (ICN1) leads to repression of miR-451 and miR-709. ICN1 de-
creases expression of these miRNAs by inducing degradation of the E2a tumor suppressor, 
which transcriptionally activates the genes encoding miR-451 and miR-709. Both miR-451 
and miR-709 directly repress Myc expression. In addition, miR-709 directly represses 
expression of the Akt and Ras-GRF1 oncogenes. We also show that repression of miR-451 
and miR-709 expression is required for initiation and maintenance of mouse T-ALL. miR-
451 but not miR-709 is conserved in humans, and human T-ALLs with activating NOTCH1 
mutations have decreased miR-451 and increased MYC levels compared with T-ALLs with 
wild-type NOTCH1. Thus, miR-451 and miR-709 function as potent suppressors of onco-
genesis in NOTCH1-induced mouse T-ALL, and miR-451 influences MYC expression in 
human T-ALL bearing NOTCH1 mutations.
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Noncommercial–Share Alike–No Mirror Sites license for the first six months   
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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(Takamizawa et al., 2004; Lu et al., 2005; Volinia et al., 2006), 
its reduced expression correlates with poor patient outcomes 
(e.g., lung cancer; Takamizawa et al., 2004), and let-7 nor-
mally represses the expression of RAS, including its onco-
genic forms (Johnson et al., 2005). Additionally, transduction 
of let-7 reduces lung tumor growth in mice (Ortholan et al., 
2009). Here, we report reduced tumor suppressor miRNA 
activity that is required for tumor initiation. We identified two 
miRNAs, miR-451 and miR-709, which are transcriptional 
targets of the E2a tumor suppressor, which is degraded upon 
ICN1 induction in mouse T-ALL cells. We report a coopera-
tive loop in which miR-451 and miR-709 must be down-
regulated for initiation and maintenance of ICN1-induced 
T-ALL and which together directly target and reduce the 
expression levels of several oncogenes, such as Myc, Akt, 
and Ras-GRF1.
REsULTs
Reduced miR-451 and miR-709 up-regulate Myc,  
Akt, and Ras-GRF1
To elucidate tumorigenic pathways that cooperate with acti-
vated Notch1 in leukemogenesis in the absence of detectable 
genomic alterations, we performed miRNA expression pro-
filing of normal CD4+CD8+ thymocytes; benign, polyclonal, 
cells with polyclonal TCR chain rearrangements, followed 
by tumorigenic CD4+CD8+ cells with monoclonal TCR 
chain rearrangement paired with diverse TCR chains. Thus, 
malignant transformation follows pre-TCR signaling but sets 
in before termination of TCR rearrangement (Li et al., 2008), 
and mice develop overt T-ALL between 6 and 8 wk after BM 
transplantation. Several genes regulating the development and 
proliferation of immature T cells, including Myc, Akt, and Ras-
GRF1, are specifically up-regulated in ICN1-overexpressing 
T-ALL tumor cells (Li et al., 2008). These appear to be critical 
in oncogenesis, because Myc is an essential oncogenic path-
way downstream of Notch1 (Palomero et al., 2006; Sharma   
et al., 2006; Weng et al., 2006; Li et al., 2008), and Akt and 
Ras-GRF1 are components of cooperating oncogenic path-
ways in human T-ALL (Lübbert et al., 1990; Palomero et al., 
2007; Gutierrez et al., 2009). Thus, in terms of elevated onco-
gene expression mouse T-ALL resembles human T-ALL in spite 
of its genomic stability because (a) >50% of human T-ALL 
cases have mutationally activated NOTCH1 and overexpress 
ICN1 (Weng et al., 2004); (b) ICN1 directly regulates Myc by 
binding to regulatory sequences in the Myc promoter (Palomero 
et al., 2006); (c) ICN1-mediated activation of Myc is required 
to maintain leukemic growth (Palomero et al., 2006; Sharma 
et al., 2006; Weng et al., 2006); (d) mouse and human ICN1 
increases PI3K/Akt activity and prolongs the survival of leu-
kemic cells (Sade et al., 2004; Palomero et al., 2007; Gutierrez 
et al., 2009); and (e) the overall patterns of NOTCH1-mediated 
gene expression in human and mouse T-ALLs are remark-
ably similar (Sanda et al., 2010). Thus, the majority of human 
T-ALLs with NOTCH1 gene mutations share many features 
in common with the ICN1-induced mouse model, including 
dysregulated Myc and Akt expression and repression of cell 
cycle inhibitors.
Because mouse ICN1-induced T-ALL displays globally 
altered gene expression in spite of genomic stability (Li et al., 
2008), we considered the possibility that altered expression of 
micro RNAs (miRNAs) might be an important contributor 
to malignant transformation of T cells. miRNAs are known 
to affect developmental transitions in T cells (Li et al., 2007), 
and aberrantly expressed miRNAs have been shown to play 
important roles in malignant transformation in other tumor 
types. For example, increased expression of specific miRNAs 
such as miR-17–92 cluster drives leukemogenesis in mice 
(He et al., 2005; O’Donnell et al., 2005), indicating that 
miRNAs could function as oncogenes (oncomirs). Indeed, a 
novel activating translocation affecting the miR-17–92 clus-
ter was recently described that coincides with a rearrange-
ment that activates Notch1 (Mavrakis et al., 2010). Increased 
miR-19 was shown to act through multiple negative regula-
tors of the PI3 kinase pathway.
Conversely, miRNAs may function as tumor suppressors, 
although it has been more difficult to causally connect miRNA 
inactivation to tumor initiation. Recent studies indicate tumor 
suppressive functions during maintenance and metastasis. In the 
best example, let-7 is considered a tumor suppressor miRNA, 
because  its  expression  is  reduced  in  numerous  cancers 
Figure 1.  miR-451 and miR-709 are robustly reduced in T-ALL.  
(A) Hierarchical clustering of differentially expressed miRNA genes in normal 
CD4+CD8+ thymocytes (N), nonmalignant ICN1-overexpressing CD4+CD8+ 
cells (NT), and T-ALL tumor CD4+CD8+ cells (TU) detected by LNA-based 
miRNA expression profiling. Red denotes up-regulated expression and blue 
denotes down-regulated expression. The scale is log2. Asterisks indicate  
miR-451 and miR-709. (B) Independent validation of down-regulated expres-
sion miR-451 and miR-709 by qRT-PCR in N, NT, and TU. RNU6B was used as 
an endogenous control to normalize expression. **, P < 0.01; ***, P < 0.001. 
Relative expression (%) compared with N was calculated. Data are shown as 
mean ± SD for triplicate experiments. The large dynamic range of the qRT-
PCR assay likely accounts for the very large reduction in expression detected 
in this assay compared with microarray expression profiling in Fig. 1 A.JEM VOL. 208, April 11, 2011 
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analysis. We  used  computational  algorithms  (Lewis  et  al., 
2003; John et al., 2004) to predict the targets of miR-451 and 
miR-709. We identified the Myc oncogene as a potential 
target of both miRNAs, and the Akt and Ras-GRF1 onco-
genes as potential targets of miR-709 (Fig. 2 A). Myc is known 
to be a direct and essential target of the Notch1-containing 
transcriptional complex in the pathogenesis of both human 
and mouse T-ALL (Palomero et al., 2006; Sharma et al., 2006; 
Weng et al., 2006), but it is unclear whether transcriptional 
activation by ICN1 is sufficient for malignant transformation. 
An attractive hypothesis is that miR-451 and miR-709 are 
down-regulated as a mean to potentiate ICN1-induced over-
expression of Myc.
To experimentally validate these predictions, we reconstituted 
miR-451 and miR-709 by transfection (Fig. S2) or retroviral in-
fection (Fig. 2 B and Fig. 3) of T-ALL cells back to physiological 
levels found in normal CD4+CD8+ thymocytes (compare 
Fig. S2 and Fig. 3 B 
with Fig. 1 B)  and 
examined Myc, Akt, 
CD4+CD8+ ICN1-overexpressing cells, and malignant, mono-
clonal T-ALL cells (Fig. 1 A). Microarray analysis revealed 
several consistently dysregulated miRNAs during the pro-
gression of the leukemogenesis, including the known tumor 
suppressor miRNAs let-7d (Takamizawa et al., 2004; Johnson 
et al., 2005; Lu et al., 2005; Volinia et al., 2006; Lee and Dutta, 
2007), miR-15a, and miR-16 (Bonci et al., 2008; Calin et al., 
2005; Cimmino et al., 2005), as well as miR-451 and miR-709, 
which have not previously been linked to T-ALL oncogenesis. 
Both miR-451 and miR-709 are dynamically regulated during 
normal T cell development (Fig. S1 A) and are progressively 
down-regulated during T-ALL transformation first in be-
nign polyclonal cells and further in malignant monoclonal cells 
(Fig. 1 B), suggesting that they function as tumor suppressors.
Because miR-451 and miR-709 demonstrated the most 
robust differential expression (and a consistent trend of down-
regulation)—transitioning from normal thymocytes (N), to 
benign polyclonal (NT), to malignant monoclonal tumor 
(TU) samples—and because these were previously uncharac-
terized miRNAs, we pursued these two miRNAs for further 
Figure 2.  miR-451 and miR-709 repress 
Myc; miR-709 also represses Akt and  
Ras-GRF1. (A) Computationally–predicted 
miRNA–mRNA interactions between miR-451 
and the 3UTR of Myc (15–21) miR-709, and 
the 3UTR of Myc (125–132), miR-709 and 
the 3UTR of Akt (670–677), miR-709 and the 
3UTR of Ras-GRF1 (180–187); all miRNA 
binding sites were predicted by TargetScan 
(Lewis et al., 2003). The miR-709 binding site 
in the 3UTR of Myc was also predicted by 
MIRANDA (John et al., 2004). (B) Expression of 
miR-451 and miR-709 at physiological levels 
(demonstrated in Fig. 3 B) represses target 
mRNA and protein levels in T-ALL tumor cells. 
Quantitative analysis of Myc, Akt, and Ras-
GRF1 mRNA expression (left) and protein 
expression (right) in T-ALL tumor cells in-
fected with retroviruses expressing no miRNA 
(Vector), miR-451 (451), miR-709 (709), or 
both (451+709) as indicated. GAPDH mRNA 
was used as control for mRNA expression. 
Relative mRNA expression (%) compared with 
Vector was calculated. Data are shown as 
mean ± SD for triplicate experiments. **,  
P < 0.01; ***, P < 0.001. -Actin was used as 
loading control in Western blotting (right).  
(C) Firefly luciferase constructs possessing WT 
3UTRs (pGL3-Myc, pGL3-Akt, and pGL3-Ras-
GRF1) or point mutant 3UTRs (corresponding 
to seed region of miR-451 and miR-709) of 
Myc, Akt, or Ras-GRF1 (pGL3-Myc-mut-451, 
pGL3-Myc-mut-709, pGL3-Akt-mut-709 and 
pGL3-Ras-GRF1-mut-709) were co- 
transfected with renilla luciferase constructs 
into NIH-3T3 cells alone (Mock), with a nonspe-
cific control (Control), or with a miR-451 or 
miR-709. Firefly luciferase activity was normal-
ized to renilla luciferase activity. Relative lucifer-
ase activity compared with Mock is shown.  
**, P < 0.01, ***, P < 0.001. Data are shown as 
mean ± SD for triplicate experiments.666 miR-451: a tumor suppressor in T-ALL | Li et al.
Reduction of miR-
451 and miR-709 
is essential  
for maintenance  
of T-ALL
To study the function of miR-451 and miR-709 in T-ALL 
leukemogenesis, we expressed physiological levels (compared 
with normal CD4+CD8+ thymocytes; Fig. 1 B) of these 
miRNAs in ICN1-transduced T-ALL cells and adoptively 
transferred these cells into nude mice. Co-transfection (Fig. S2) 
or retroviral expression (Fig. 3) of miR-451 and miR-709 
into ICN1-induced T-ALL cells delayed tumor development 
compared with controls (Fig. 3 C and Fig. S2 C). At 48 h after 
transfection or retrovirus infection, the levels of miR-451 
and miR-709 approximated the levels of these miRNAs in 
normal CD4+CD8+ thymocytes (Fig. 1 B). miRNA-targeted 
oncoprotein levels (Myc, Akt, and Ras-GRF1; Fig. 2 B) and 
the levels of miR-451 and miR-709 were measured after 
introduction of the miRNA (Fig. 3 B, left, and Fig. S2 B) and 
at the time that overt T-ALL developed in the mouse (Fig. 3 B, 
right), showing that reconstitution of these miRNAs to phys-
iological levels delayed the growth of ICN1-induced tumor 
cells. miR-451 and miR-709 are expressed from the same 
transcript as GFP, and miRNA expression is directly corre-
lated with GFP expression (Fig. S1 B). The tumors that even-
tually developed contained a large proportion of cells that lost 
GFP expression (Fig. 3, C and D). The control vector did not 
result in a loss of GFP expression, indicating that the expres-
sion of the miRNAs inhibited tumor growth. Thus, T-ALL 
and Ras-GRF1 mRNA and protein levels. Our data indicate 
that we achieved near physiological reconstitution of miR-
451 or miR-709, which repressed Myc at the mRNA and 
protein levels, and that these two miRNAs acted synergis-
tically to reduce Myc levels when coexpressed in T-ALL cells. 
In addition, reconstitution of miR-709, but not miR-451, 
repressed Akt and Ras-GRF1 mRNA and protein levels 
(Fig. 2 B and Fig. S2 D).
To  experimentally  define  the  miR-451  and  miR-709 
binding sites in the 3 untranslated regions (3UTRs) of the 
predicted target genes, we cloned WT or point mutant versions 
of the Myc, Akt, or Ras-GRF1 3UTR gene segments into 
firefly luciferase reporter vectors and performed dual luciferase 
assays upon reconstitution of miR-451 and miR-709 (Fig. 2 C). 
Co-transfection of miR-451 or miR-709, but not a control 
miRNA, specifically decreased expression of firefly luciferase 
reporter mRNAs possessing the WT Myc 3UTR. When the 
predicted seed region binding sequences in the Myc 3UTR 
were mutated, firefly luciferase expression returned to base-
line levels, implicating these sequences in miRNA binding. 
Similarly, co-transfection of miR-709 but not control miRNA 
specifically  decreased  firefly  luciferase  activity  in  reporter 
mRNAs possessing WT Akt and Ras-GRF1 3UTRs, but 
not miR-709 seed region binding sequence point mutant 
3UTRs. These mutants in miR-451 or miR-709 binding sites 
completely are resistant to miR-451– and miR-709–mediated 
repression, and provide further evidence that Myc is a genuine 
target of miR-451 and miR-709 and that Akt and Ras-GRF1 
are genuine targets of miR-709.
Figure 3.  Physiological expression of 
miR-451 and miR-709 slows T-ALL tumor 
growth in vivo. (A) Schematic representation 
of the experimental design. ICN1-induced  
T-ALL formation was initiated by transplantation 
of BM cells transduced with MSCV retrovirus 
encoding ICN1-DsRed into BALB/c mice. 
ICN1-DsRed–overexpressing T-ALL cells were 
harvested and infected with a CMMP retrovi-
rus vector encoding GFP without or with miR-
451, miR-709, or both. DsRed+GFP+ cells were 
then sorted by FACS and transplanted into 
Nu/Nu recipient mice. (B) Expression of miR-451 
and miR-709 in the T-ALL cells infected with-
out (Vector) or with miR-451 (451), miR-709 
(709), or both (451+709) were assessed by 
miRNA quantitative RT-PCR before adoptive 
transfer (left) or after tumor formation (right). 
RNU6B was used as an endogenous small 
RNA control to normalize miRNA expression. 
Fold induction compared with Vector was 
determined. Data are shown as mean ± SD for 
triplicate experiments. **, P < 0.01; ***, P < 0.001. 
(C) Kaplan-Meier analysis of survival time of 
Nu/Nu recipients in each group is shown.  
P < 0.01 (Vector vs. 451); P < 0.01 (Vector vs. 
709); and P < 0.01 (Vector vs. 451+709).  
(D) FACS analysis of miR-451 and/or miR-709 
(GFP) and ICN1 (DsRed), as well as CD4  
and CD8 expression in T-ALL tumor cells  
after infection and FACS sorting before  
adoptive transfer (Input) or after tumor for-
mation (Output).JEM VOL. 208, April 11, 2011 
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retrovirus expressing ICN1 together 
with DsRed and a retrovirus express-
ing physiological levels of miR-451 and 
miR-709 together with GFP. The in-
fected cells were injected into suble-
thally irradiated recipients (Fig. 4 A). 
Expression of ICN1-DsRed and the 
GFP vector control led to widespread tumor formation in 
several tissues, including liver, spleen, BM, and multiple LNs 
as determined by whole body (Fig. 4 B) and lymphoid organ 
imaging (Fig. 4 C), histopathology (Fig. 4 D and Fig. S3 B), 
FACS analysis (Fig. 4 E), and immunohistochemistry (Fig. S3, 
C and D). In contrast, ectopic expression of miR-451 and 
miR-709 completely blocked tumor formation in any site by 
any of these metrics. Moreover, the spleens and LNs harvested 
from mice expressing miR-451 and miR-709 were normal 
compared with organs from tumor-bearing mice, which were 
grossly enlarged (Fig. 4 C). FACS analysis of LNs, BM, lung, 
and livers harvested from mice infected with the empty vector 
control demonstrated numerous GFP+DsRed+ tumor cells 
composed mostly of CD4+CD8+ cells and CD4CD8+ cells, 
outgrowth results from selection against the cells with increased 
miR-451 and miR-709 expression. The CD4/CD8 staining 
in the second column shows that all tumor cells exhibited the 
same CD4/CD8 expression profile. Collectively, our data show 
that physiological levels of miR-451 and miR-709 are sufficient 
to repress the expression levels of Myc, Akt, and Ras-GRF1 
and that repression by these miRNAs accelerates tumor cell 
growth during ICN1-induced T-ALL oncogenesis.
Reduction of miR-451 and miR-709 is essential  
for initiation of T-ALL
To identify potential roles for miR-451 and miR-709 as 
tumor suppressors during the initiation of T-ALL by ICN1, 
we co-infected Lin-negative normal mouse BM cells with a 
Figure 4.  Coordinate expression of  
miR-451 and miR-709 blocks ICN1- 
induced tumor initiation in vivo. (A) Sche-
matic representation of the experimental 
design. Lin BM cells harvested from BALB/c 
mice were infected with a retrovirus express-
ing DsRed and ICN1 and with a retrovirus 
expressing GFP with or without miR-451 and 
miR-709. DsRed+GFP+ cells were sorted by 
FACS and adoptively transferred into suble-
thally irradiated (lightning bolt) syngeneic 
mice. T-ALL was assessed at 6 wk after BM 
transplantation. (B) Whole-body imaging of 
mice expressing ICN1-DsRed (red) and GFP 
(green) without (Vector, left) or with miR-451 
and miR-709 (451+709, right) are shown. Bar, 
25 mm. (C) LNs and spleens harvested from 
Vector and 451+709 recipients are shown. Bar, 
15 mm. (D) Hematoxylin and eosin (H&E) 
staining to detect tumor infiltrates in kidney, 
liver, lung, spleen, and BM of recipients of BM 
cells transduced with vector or miR-451 and 
miR-709 (451+709). Blood smears were as-
sessed by Giemsa staining (right panel). Scale 
bar, 10 µm. (E) FACS analysis of DsRed+GFP+ 
cells in blood, BM, liver, LN, or lung after 
transplantation of BM cells. BM cells trans-
duced with neither ICN1-DsRed nor miR-451-
miR-709-GFP are shown as a control. CD4 
and CD8 expression on the DsRed+GFP+ cells 
from control mice were also analyzed.  
(F) Percentage of DsRed+GFP+ cells in the blood 
at indicated times after BM transplantation  
(n = 8 in each group, P < 0.001). (G) Kaplan-
Meier analysis of survival time in each group 
(n = 8) is shown. P < 0.0001 by log-rank test.668 miR-451: a tumor suppressor in T-ALL | Li et al.
Our data clearly indicate E47-dependent activation of WT 
but not E-box mutant miR-451 and miR-709 promoters 
(Fig. 5 C). T-ALL cells normally have very little E2a protein 
(Li et al., 2008,) and thus the effect of an E2a knockdown 
cannot be studied in these cells. Instead, to functionally link 
E2a activation to miR-451 and miR-709 expression in T-ALL, 
we ectopically expressed E2a. ICN1-DsRed tumor cells were 
transduced with the empty retroviral vector or retroviral 
construct  encoding  a  nondegradable  mutant  form  E47 
(Fig. 5 D). Restoration of E47 significantly induced miR-451 
and miR-709 expression in the ICN1 tumor cells (Fig. 5 E) 
and reduced ICN1-tumor cell growth (Fig. 5 F) compared 
with cells transduced with retroviral empty vector controls. 
Together, these data demonstrate that miR-451 and miR-709 
are direct transcriptional targets of E2a and indicate a mecha-
nism of Notch1-dependent suppression of these miRNAs 
leading to derepression of T-ALL oncogenes (Fig. 5 G).
NOTCH1 mutant human T-ALL exhibit decreased miR-451 
and increased Myc
To address the question whether reduced miRNA expression 
could also contribute to human T-ALL, we examined human 
miR-451 (humans lack a miR-709 homologue) and its target 
MYC levels in human T-ALLs that have been segregated into 
groups based upon activating NOTCH1 mutation status, as 
well as in normal human thymocytes (Fig. 6 A). The charac-
teristics of these primary T-ALL patient samples and cell lines 
are listed in Table S1. We identified lower miR-451 expres-
sion levels in primary samples harboring activating NOTCH1 
mutations (middle) and T-ALL cell lines expressing the ICN1 
protein (right), when compared with patient samples that 
lacked NOTCH1 gene mutations (left) or normal thymocytes 
(control; Fig. 6 A). The MYC levels were significantly higher 
in T-ALL cell lines expressing the ICN1 than in primary 
patient samples lacking activating NOTCH1 mutations. Im-
portantly, analysis of cell surface marker expression did not 
indicate any correlation between cell differentiation stage and 
miR-451 expression, suggesting that maturational arrest alone 
did not explain these differences (Table S1). These data indi-
cate that miR-451 is selectively reduced in T-ALLs exhibiting 
mutational activation of NOTCH1, suggesting that miR-451 
functions as a tumor suppressor in NOTCH1-driven human 
and mouse T-ALL.
We also analyzed the expression levels of miR-451 and 
MYC in a panel of established human T-ALL cell lines. We 
previously reported that ICN1 is constitutively overexpressed 
in most of the T-ALL cell lines, as a result of genetic mutations 
of NOTCH1 and/or FBXW7 (O’Neil et al., 2007; see Table S1 
for ICN1 expression and genetic status of NOTCH1 and 
FBXW7 in the 11 T-ALL cell lines). All of the ICN1-positive 
T-ALL cell lines demonstrated very low levels of miR-451 and 
expressed increased levels of MYC (Fig. 6 A), presumably 
reflecting selection for T-ALL cells with very high MYC 
levels and proliferative rates during their establishment and 
maintenance in tissue culture. Computational analysis pre-
dicted that human miR-451 also targets the human MYC 
as shown by CD4/CD8 staining (Fig. 4 E, bottom row) con-
sistent with ICN1-induced T-ALL (Li et al., 2008). In con-
trast, mice expressing miR-451 and miR-709 contained no 
detectable tumor cells. During the early stages after BM 
transplantation, DsRed+GFP+ cells are present in both of 
control mice and miR-451+miR-709 mice, reflecting a poly-
clonal and nontumorigenic stage (Li et al., 2008); however, at 
later stages after bone marrow transplantation, DsRed+GFP+ 
cells expanded rapidly only in the mice expressing the control 
vector, indicating outgrowth of monoclonal T-ALL tumors. 
No DsRed+GFP+ cells could be detected at 6–8 wk after 
transplantation of BM cells expressing miR-451+miR-709 
(Fig. 4 F and Fig. 4 G). It is important to emphasize that these 
mice exhibited normal thymic development and generated 
nonmalignant ICN1 overexpressing CD4+CD8+ cells in pe-
ripheral lymphoid tissue. Thus, the expression of miRNAs at 
levels found in normal thymocytes specifically inhibits malig-
nant transformation after pre-TCR signaling. The absence of 
tumor cells in the BM, normal thymic development, and the 
appearance of comparable numbers of nonmalignant (predomi-
nantly CD4+CD8+) GFP+DsRed+ cells in peripheral tissues   
3 wk after BM transplantation (Fig. S4) indicates that the 
combined expression of ICN1 and miR-451 and miR-709 did 
not simply block T cell differentiation or migration. Together, 
these data indicate that miR-451 and miR-709 are tumor 
suppressors whose expression must be down-regulated during 
ICN1-induced T-ALL transformation.
miR-451 and miR-709 are E2a transcriptional target genes
To investigate the mechanism of reduced miR-451 and 
miR-709, we performed miRNA-specific RT-PCR. ICN1 in-
duction led to reduced expression of primary (pri-miRNAs), 
premature (premiRNAs), and mature forms of both miR-451 
and miR-709 (unpublished data), arguing against posttran-
scriptional down-regulation of these miRNAs. To test for a 
mechanism of transcriptional down-regulation, we examined 
promoter regions of these genes and noted 4 E-box binding 
motifs (CANNTG) in the miR-451 promoter and 2 E-box 
binding motifs in the miR-709 promoter (Fig. 5 A). Because 
(a) E2a-encoded proteins are essential for B cell and T cell 
development (Bain et al., 1994; Zhuang et al., 1994; Ikawa   
et al., 2006); (b) E2a-defieient mice regularly develop T-ALL 
(Bain et al., 1997); and (c) E2a proteins are rapidly degraded 
in ICN1-induced T-ALL (Li et al., 2008), we examined tran-
scriptional regulation of miR-451 and miR-709 by E2a.
Chromatin  immunoprecipitation  (ChIP)  for  normal 
CD4+CD8+ thymocytes using an anti-E2a antibody demon-
strated a 25-fold enrichment of the miR-451 promoter and 
a 15-fold enrichment of the miR-709 promoter compared 
with controls (Fig. 5 B) demonstrating that endogenous E2a 
occupies these miRNA promoters in normal thymocytes. 
To determine whether E2a transcriptionally activates these 
promoters through binding to E-box motifs, we cloned WT 
or E-box deletion mutant miR-451 or miR-709 promoters into 
luciferase-expressing constructs and measured luciferase ac-
tivity when co-transfected with E47, one of splice forms of E2a. JEM VOL. 208, April 11, 2011 
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(GSI, MRK-003), a derivative of which is currently used in clin-
ical trials of T-ALL (Paganin and Ferrando, 2011). We and others 
have previously reported that GSI treatment down-regulates 
MYC and inhibits T-ALL cell growth (Palomero et al., 2006; 
Sharma et al., 2006; Weng et al., 2006). In this experiment, 
MYC levels were reduced in each of the four cell lines over-
expressing miR-451 compared with controls (Fig. 6 D, green 
bars), and MYC levels were further down-regulated after GSI 
treatment for each cell line (Fig. 6 D, orange bars). Importantly, 
up-regulation  of  miR-451  combined  with  GSI  treatment 
synergistically inhibited T-ALL cell growth (Fig. 6 E). Collec-
tively, these results demonstrate that restoration of miR-451 
expression could be considered as a novel therapeutic approach 
to reduce both the levels of MYC expression and T-ALL cell 
growth, especially in the context of GSI treatment.
mRNA (Fig. 6 B). Transfection of miR-451 specifically de-
creased expression of firefly luciferase reporter mRNAs possess-
ing the WT MYC 3UTR, but not mutated 3UTR (Fig. 6 C), 
indicating that MYC is a direct target of miR-451.
To mechanistically link altered miR-451 expression to the 
biology of human T-ALL, we transduced miR-451 and the 
empty GFP vector into four representative ICN1+ human   
T-ALL cell lines (Fig. S5), which are characterized by very low 
miR-451 expression levels (Fig. 6 A). Expression of miR-451 
on its own was not sufficient to inhibit the growth of these   
T-ALL cell lines (Fig. S5 B). Because miR-451 acts syner-
gistically with activated NOTCH signaling in mouse T-ALL, 
we analyzed the effect of programmed expression of miR-
451 in human T-ALL cell lines when combined with inhi-
bition of NOTCH1 signaling using a -secretase inhibitor   
Figure 5.  E2a transcriptionally activates 
miR-451 and miR-709. (A) Schematic pre-
sentation of miR-451 and miR-709 promot-
ers. Positions (KB) of consensus E-box binding 
motifs (CANNTG) are indicated relative to the 
major transcription start site (TSS). (B) Quanti-
tative ChIP analysis for normal mouse 
CD4+CD8+ thymocytes demonstrating E2a 
binding on miR-451 and miR-709 promoters. 
ChIP analysis was performed using an anti-
E2A antibody or normal rabbit IgG (IgG nega-
tive control), followed by a quantitative PCR 
analysis using a negative control primer (Con-
trol) or specific primers for either miR-451 or 
miR-709 promoter. Fold enrichment was de-
termined by a standard curve for the non-
ChIP samples (input DNA). Data are presented 
as mean ± SD for triplicate experiments.  
**, P < 0.01; ***, P < 0.001. (C) Firefly luciferase 
constructs possessing miR-451 or miR-709 
promoter with WT (orange) or mutated E-box 
motifs (red) was co-transfected with a renilla 
luciferase construct and an E47-expressing 
vector into NIH-3T3 cells. Firefly luciferase 
activity was normalized to renilla luciferase 
activity. Relative luciferase activity compared 
with the control vector without E-box motifs 
(green) was determined. Data are presented as 
mean ± SD for triplicate experiments. ***, P < 
0.001. (D) Western Blot analysis of ectopically 
expressed, nondegradable mutant form of E47 
(MSCV-IRES-GFP-MmE47) in ICN1-tran-
formed tumor cells (E47) compared with un-
infected control (-) and MSCV-IRES-GFP 
retrovirus-infected ICN1-tranformed tumor 
cells (Vector). -Actin, loading control.  
(E) miR-451 and miR-709 were measured  
by qRT-PCR in ICN1-trasnformed tumor cells expressing the nondegradable mutant form of E47 (E47) or control vector (Vector). Data are presented as 
mean ± SD for triplicate experiments. **, P < 0.01; ***, P < 0.001. (F) DsRed-ICN1 tumor cells were infected with MSCV-IRES-GFP-MmE47 (E47) or MSCV-
IRES-GFP (Vector). GFP+DsRed+ cells were sorted and cultured, and cell growth was measured on days 1, 3, or 5. Data are presented as mean ± SD for 
triplicate experiments. *, P < 0.05. (G) Model for mechanism of Notch1-induced suppression of miR-451 and miR-709 in T-ALL. Increased Notch1 activity 
facilitates degradation of E2a, leading to transcriptional down-regulation of miR-451 and miR-709 that posttranscriptionally de-represses the T-ALL on-
cogenes Myc, Akt, and Ras-GRF1, which, in turn, promotes T-ALL. In addition, Notch1 has been shown to directly increase Myc transcription implying that 
Notch1 cooperates with reduced miR-451 and miR-709 to increase Myc expression.670 miR-451: a tumor suppressor in T-ALL | Li et al.
nonmalignant ICN1-overexpressing cells intact, indicating 
that reduced expression of these tumor suppressor genes was 
required for transformation. Additionally, tumors developed with 
a significant delay when ICN1-overexpressing established tumor 
cells were transferred into nude mice after transduction with 
miR-451 or miR-709 to achieve levels similar to those in nor-
mal thymocytes (Fig. 3 and Fig. S2). These results clearly indicate 
the role of these miRNAs as tumor suppressors in T cell leu-
kemogenesis. When tumor cells were transfected and the tumors 
that formed after a delay had selective loss of miRNA expres-
sion (Fig. 1 B), again supporting the selection for loss of these 
miRNAs in concert with ICN1 overexpression in T-ALL.
It is noted that copy number losses at these miRNA gene 
loci were not observed in mouse T-ALL, human primary T-ALL 
patient samples or cell lines by array-based CGH analysis (Li 
et al., 2008; Gutierrez et al., 2009; unpublished data). Thus, ge-
netic deletion likely does not account for reduced expression 
of these miRNA gene loci in tumor cells. Our data demonstrate 
that ICN1 induction leads to E2a degradation and thus to reduced 
levels of miR-451 and miR-709, but we cannot exclude the 
possibility that epigenetic modifications can also participate 
in reducing expression of these miRNAs. Dicer-independent, 
but Argonaute2-dependent, biogenesis of miR-451 was re-
cently reported (Cheloufi et al., 2010; Cifuentes et al., 2010). 
DIsCUssION
We identified miR-451 and miR-709 as novel tumor sup-
pressor miRNAs that normally repress the initiation and 
maintenance of mouse Notch1-driven leukemogenesis in vivo. 
Myc is essential for Notch1-induced T-ALL tumor formation 
in mice (Li et al., 2008) and has been shown to be an essential 
target of NOTCH1 in the maintenance of proliferation and 
viability in human and mouse T-ALL. Both miR-451 and 
miR-709 target Myc and Myc mRNA and protein levels are 
reduced by fivefold after transduction of tumor cells that 
results in near physiological levels of expression of miR-451 
and miR-709. When both miRNAs were introduced to-
gether, Myc levels were reduced by 10-fold, indicating that 
they act independently of other mechanisms to reduce Myc 
expression (Fig. 2 B).
It has been reported that miR-451 is underexpressed in cyto-
genetically normal acute myeloid leukemia patients (Whitman 
et al., 2010), and miR-451 functions as either a tumor sup-
pressor (Gal et al., 2008; Nan et al., 2010) or an oncogene 
(Godlewski et al., 2010a,b) in human glioma cells. Here, we 
provide the first evidence showing that expression of both 
miR-451 and miR-709 in ICN1-expressing BM completely 
blocked the initiation of T-ALL in recipient mice (Fig. 4) 
leaving normal T cell development and the generation of 
Figure 6.  Activating NOTCH1 mutations 
in human T-ALL demonstrate down- 
regulation of miR-451 and up-regulation 
of MYC. (A) human miR-451 and MYC RNA 
levels were assessed by quantitative RT-PCR 
in primary T-ALL samples clustered by WT or 
activating mutant (MUT) NOTCH1 and in 11 
ICN1-positive T-ALL cell lines. RNA expres-
sion levels of miR-451 or MYC were normal-
ized by RNU1A or GAPDH, respectively, and 
fold expression is presented compared with 
the mean of normal thymocytes from two 
independent donor individuals. Significance 
was evaluated by the unpaired Student’s  
t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
Data are shown as mean ± SEM for each 
group. (B) Computationally predicted 
miRNA–mRNA interactions between human 
miR-451 and the 3UTR of human MYC (15–
21, pink); miRNA binding sites were pre-
dicted by MIRANDA. (C) Firefly luciferase 
constructs possessing WT 3UTRs or point 
mutant 3UTRs (corresponding to seed re-
gion of miR-451) of human MYC was co-
transfected with renilla luciferase constructs 
into NIH-3T3 cells alone (Mock), with a non-
specific control (Control) or with a miR-451 (451). Firefly luciferase activity was normalized to renilla luciferase activity. Relative luciferase activity 
compared with Mock is shown. Data are presented as mean ± SD for triplicate experiments. ***, P < 0.001. (D) Four T-ALL cell lines were infected with 
the CMMP retrovirus encoding GFP and miR-451 (451) or no miRNA (Vector). After selection of GFP-positive cells by flow cytometry, the cells were 
treated without DMSO or with 1 µM MRK-003 -secretase inhibitor (GSI) for 3 d. Human MYC RNA levels were assessed by quantitative RT-PCR and 
normalized by GAPDH. Fold reduction is expressed as levels relative to levels in normal thymocytes. Error bars represent ± SD for triplicate experi-
ments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (E) 4 T-ALL cell lines transduced with miR-451 (451) or no miRNA (Vector) were treated without DMSO 
or with 1 or 3 µM MRK-003 GSI for 5 d. Cell viability was measured by CellTiter-Glo assay and reported as percentage of DMSO-treated control.  
Error bars represent ± SD for triplicate experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001.JEM VOL. 208, April 11, 2011 
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Cancer Institute (Boston, MA). All animal procedures were performed in 
compliance with the guidelines of the Dana-Farber Cancer Institute Ani-
mal Resources Facility, which operates under regulatory requirement of 
the U.S. Department of Agriculture and Association for Assessment and 
Accreditation of Laboratory Animal Care. Experimental protocols were   
approved by the Animal Care and Use Committee of the Dana-Farber 
Cancer Institute.
miRNA precursor cloning and construction of retroviral vectors
miR-451 and miR-709 precursors were PCR-amplified from mouse ge-
nomic DNA. Amplified fragments were subcloned into the pEGP-miR clon-
ing vector (Cell Biolabs, Inc.) between BamH1 and NheI sites, and then the 
fragment of EF-1 Promoter/human -globin intron containing the miRNA 
precursor was subcloned into a bicistronic retroviral vector MSCV-IRES-GFP 
between EcoRI and SnaBI. To preserve the putative hairpin structure and 
endogenous processing, miRNA stem loop sequence was flanked by its native 
intron sequence. The sequences of PCR primers for miR-451 precursor were 
(forward)  5-TCGAGGATCCCTGGGTACCCCACCTCCAGAGCCT-3 
and  (reverse)  5-TCGAGCTAGCAAAATGTACCCTTTCCCCCAAC-
CCCATT-3. The sequences of PCR primers for miR-709 precursor were 
(forward) 5-TCGAGCTAGCAAGGAGAGAGAAAACGGACTCCTCTA-
GGTT-3 and (reverse) 5-TCGAGCTAGCAAGGAGAGAGAAAACGGA-
CTCCTCTAGGTT-3. The miR-451+miR-709 fragment was generated by 
overlapping PCR. Another bicistronic retroviral vector, CMMP-IRES-EGFP, 
was used to construct the miRNA retroviral vector. The PCR-amplified frag-
ment was cloned into the retroviral vector under control of the cytomegalovirus 
promoter. The miRNA transgene expression was confirmed by real-time PCR. 
The sequences of PCR primers for the miR-451 precursor were (forward) 
5-TCCTCGAGCTGGGTACCCCACCTCCAGAGCCT-3 and (reverse) 
5-TAGGATCCAAAATGTACCCTTTCCCCCAACCCCATT-3. The  se-
quences of PCR primers for the miR-709 precursor were (forward) 5-TCCT-
CGAGAGGGTAGCCTTGAACTCAGAGATTTGCC-3  and  (reverse) 
5-TAGGATCCAAGGAGAGAGAAAACGGACTCCTCTAGGTT-3.
Retrovirus production and BM transplantation
Retroviral supernatants were produced by transfection of 293T cells with 
retroviral constructs and appropriate packaging vectors, as previously de-
scribed (Li et al., 2008). Retroviral infection and BM reconstitution were 
performed as follows: Lin (CD3, TCR-, NK1.1, DX5, CD19, Ter-119, 
Mac-1, and Gr-1) BM cells were sorted from BALB/c mice and cultured 
with Flt3L, IL-6, IL-7, and Scf (all from R&D Systems). On days 2 and 
4 after sorting, cells were subjected to retroviral infection with MSCV-
ICN1-IRES-DsRed retrovirus and CMMP-IRES-EGFP, or CMMP-miR-
451+709-IRES-EGFP retrovirus by centrifugation at 2,300 rpm for 1.5 h 
at room temperature. GFP+DsRed+ cells were collected by FACS sorting 
and injected intravenously into sublethally irradiated 4–6-wk-old syngeneic 
BALB/c recipient mice.
Ectopic expression of miR-451 and miR-709
DsRed+ICN1-overexpressing T-ALL cells were isolated from ICN1-dependent 
tumor cells in BALB/c mice after BM transplantation. Tumor cells were 
maintained in RPMI-1640 medium supplemented with 10% fetal bovine 
serum, penicillin G, and streptomycin in a humidified atmosphere containing 
5% CO2 at 37°C. DsRed+ tumor cells were infected with a GFP-expressing   
retrovirus (MSCV-IRES-EGFP) also expressing nothing (empty vector control) 
or expressing miR-451 (MSCV-miR-451-IRES-EGFP), miR-709 (MSCV-
miR-709-IRES-EGFP),  or  miR-451  and  miR-709  in  tandem  (MSCV-
miR-451+709-IRES-EGFP). After 48 h, GFP+/Ds-red+ cells were sorted, 
collected, and injected into nude (Nu/Nu; Taconic) mice.
Dual luciferase assays
miRNA target validation. 3UTR segments of mouse Myc, Akt or 
Ras-GRF1 or 3UTR segment of human MYC were amplified by PCR 
from mouse genomic DNA or human genomic DNA using the following prim-
ers: 5-CATCTAGAACTGACCTAACTCGAGGA-3 (Myc-3UTR-F) 
However, it is unlikely that this mechanism participates in   
T-ALL, because Argonaute2 expression was not reduced in 
human or mouse T-ALL (unpublished data) and pri-miR-451, 
premiR-451, and mature miR-451 were all reduced upon ICN1 
induction (unpublished data) suggesting against posttranscrip-
tional regulation of miR-451 levels.
Importantly, the human homologue of mouse miR-451 is 
robustly reduced in human T-ALLs that exhibit mutational 
activation of NOTCH1, with concomitant up-regulation of 
MYC expression similar to the results in mouse T-ALL. 
Humans do not contain miR-709, so miR-451 appears to 
subsume many of the MYC regulatory roles of both miR-451 
and miR-709 in the mouse, which could be considered an 
advantage in terms of licensing miR-451 as a potential target 
for therapeutic intervention in T-ALL. miR-709 also down-
regulates the AKT and RAS pathways in mouse T-ALL, and 
these pathways themselves are often directly mutated and 
activated in human T-ALL (Lübbert et al., 1990; Palomero et al., 
2007; Gutierrez et al., 2009). We and others have previously 
demonstrated that genetic inactivation of PTEN, or muta-
tional activation of PI3K or AKT genes occur in 47.7% of 
primary human T-ALL cases and that RAS gain-of-function 
mutations or PTPN11 deletion occurs in 9.1 or 2.1% of 
cases, respectively (Lübbert et al., 1990; Palomero et al., 2007; 
Gutierrez et al., 2009). Thus, in humans, key components of 
these pathways are often directly altered by mutation to ac-
complish the same synergy required for transformation.
In conclusion, we demonstrate the first example of miRNA-
mediated repression of tumor initiation in vivo. miR-451 is a 
suppressor of tumor initiation by acting to down-regulate MYC 
in both mouse and human T-ALL. Several miRNA gene knock-
out mice have been described (Rodriguez et al., 2007; Thai   
et al., 2007; Xiao et al., 2007) including a knockout mouse with 
targeted deletion of the DLEU2/miR-15a/miR-16-1 locus 
that predisposes the mice to chronic lymphocytic leukemia 
(Klein et al., 2010).However, the knockout locus also contains 
part of the DLEU1 gene and the DLEU2 gene and the DLEU2 
gene product are implicated as suppressors of aggressive disease. 
In contrast, in the mouse model presented here, transcriptional 
activation driven by ICN1 cooperating with reduced posttran-
scriptional inhibition by miR-451 and miR-709 of T-ALL   
oncogenes is required for tumor initiation and maintenance, 
suggesting that these miRNAs represent important biomarkers 
and possible candidates for therapeutic reconstitution.
MATERIALS AND METHODS
miRNA microarray analysis
Total RNA for miRNA expression profiling was extracted using TRIzol 
Reagent  (Invitrogen)  from  the  three  groups  of  the  mouse  cells:  control 
CD4+8+ thymocytes, nonmalignant ICN1 overexpressing CD4+8+ cells, and 
T-ALL tumor CD4+8+ cells. miRNA microarray analysis was performed 
using the mercury Hy3/Hy5 labeling kit and the mercury LNA array (ver-
sion 8.1; both from Exiqon A/S). The microarray data have been deposited in 
the GEO database under accession no. GSE27418.
Mice
BALB/c WT and BALB/c Nu/Nu mice were purchased from Taconic. All 
mice were kept in specific pathogen–free animal facilities at the Dana-Farber 672 miR-451: a tumor suppressor in T-ALL | Li et al.
and  5-GCTCTAGATTATTTACATTTCAAGGC-3  (Myc-3UTR-R);   
5-CATCTAGAAGAGGTCACAGCTGCTTCA-3 (Akt-3UTR-F) and   
5-GCTCTAGACAAGCTTGAAAAGCAATTT-3 (Akt-3UTR-R); 5-CAT-
CTAGAGGCTGTTCTCCCCACCCACTGGCA-3 (Ras-GRF1-3UTR-F)   
and 5-GCTCTAGACGTCACAGAAAGGGAGGCAGAGTCTGAGAG-
TGCA-3 (Ras-GRF1-3UTR-R), 5-CATCTAGAGGAAAAGTAAGGA-
AAACGATTCCTTCT-3 (human-MYC-3UTR-F) and 5-GCTCTAGAT-
ATTAAAGTTATTTACATTTAATGGCA-3  (human-MYC-3UTR-R). 
The segments were then cloned into a firefly luciferase reporter vector pGL3 
control vector (Promega) using the XbaI site immediately downstream from the 
stop codon of luciferase, giving rise to the pGL3-Myc, pGL3-Akt, pGL3-
Ras-GRF1, pGL3-h-MYC WT plasmid, respectively. The WT insert was 
used to generate the insert with point mutation from the site of perfect 
complementarity by using the following primers: 5-CATCTAGAACTGA-
CCTAACTCGAGGAGGAGCTGGAATCTCTCGTGAGAGTAAGGAGT-
CGCCGGCCTTCT-3 (Myc-mut-451-F) and 5-GCTCTAGATTATTTA-
CATTTCAAGGC-3 (Myc-mut-451-R); 5-GCCATAATTTTAAACC-
GGGGAAACTTAAATAGTA-3  (Myc-mut-709-F)  and  5-TACTAT-
TTAAGTTTCCCCGGTTTAAAATTATGGC-3  (Myc-mut-709-R); 
5-TACCCTGGGAGCGCGCAGTATACGTGAGCCCTTCTC-3 (Akt-
mut-F)  and  5-AGAAGGGCTCACGTATACTGCGCGCTCCCAGG-
GTA-3 (Akt-mut-R); 5-CATCTAGAGGCTGTTCTCCCCACCCAC-
TGGCA-3 (Ras-GRF1-mut-F) and 5-CATCTAGAGGCTGTTCTCC-
CCACCCACTGGCACCGCAGCGTAACGCCAGGCAGTATCCAG-
GCAGTATTG-3  (Ras-GRF1-mut-R);  5-CATCTAGAGGAAAAG-
TAAGGAATCGCCGGCCTTCTAACA-3 (human-MYC-mut-F) and   
5-GCTCTAGATATTAAAGTTATTTACATTTAATGGCA-3 (human-
MYC-mut-R). The mutant insert was cloned into pGL3-control vector using 
the same cloning site as WT, named pGL3-Myc-mut-451, pGL3-Myc-mut-709, 
pGL3-Akt-mut, pGL3-Ras-GRF1-mut, pGL3-h-MYC-mut-451 plasmid, 
respectively. WT  and  mutant  inserts  were  confirmed  by  DNA  sequencing. 
NIH3T3 cells were transfected in 12-well plates using Lipofectamine2000 
(Invitrogen) according to the manufacturer’s protocol. In brief, 30 nM miRNA 
(nonspecific mimic control, miR-451 mimic, or miR-709) was co-transfected 
with 0.6 µg of the firefly luciferase construct containing a WT or a mutated 
3UTR and 0.1 µg of the control reporter vector pRL-TK containing renilla 
luciferase (Promega). The sequences of miR-451 and miR-709 binding sites in 
WT 3UTRs or point mutant 3UTRs (corresponding to the seed region of 
miR-451 and miR-709) cloned into luciferase reporter constructs are as follows: 
mmu-miR-451-c-Myc:  WT  5-CGTGAGAGTAAGGAGAACGGTTC-3; 
mutant  5-CGTGAGAGTAAGGAGTCGCCGGC-3.  Mmu-miR-709- 
c-Myc: WT 5-CAGCCATAATTTTAACTGCCTCA-3, mutant 5-CAGC-
CATAATTTTAAACCGGGA-3. mmu-miR-709-Akt: WT 5-GTACCCT-
GGGAGCGCCTGCCTCA-3, mutant 5-GTACCCTGGGAGCGCGC-
AGTATA-3. mmu-miR-709-Ras-GRF1: WT 5-CTGCACTCTCAGC-
TCTGCCTCC-3, mutant 5-CTGCACTCTCAGACTGCAGTATC-3. 
hsa-miR-451-c-Myc:  WT  5-GGAAAAGTAAGGAAAACGATTC-3,   
mutant 5-GGAAAAGTAAGGAATCGCCGGC-3. Firefly and renilla lucif-
erase activities were measured consecutively using the dual luciferase assay (Pro-
mega) 24h after transfection. Firefly luciferase activity was normalized to renilla 
luciferase activity.
E2A  Transcriptional  activation.  A  fragment  containing  two  E-box 
motifs in the promoter region of mmu-miR-451 or mmu-miR-709 was 
PCR amplified from mouse genomic DNA by using the following primers:   
5-AATGGTACCTAGGCTGCTACCCTGATAGT-3 and 5-ATTGC-
TAGCTTTCCTCAAATGTAAGATGGA-3  for  miR-451;  5-ATGG-
TACCAATCTTCATTCGGGTGGCCATGAGTT-3 and 5-ATGC-
TAGCAACACTAGCACCTGGGGCATTCTGT-3 for miR-709. The 
PCR products were cloned into the KpnI–NheI restriction endonuclease 
cleavage sites of the pGL4.10[luc2] luciferase reporter vector (Promega) to 
generate  luciferase  reporter  construct  pGL4.10-miR-451-WT  for  mmu-
miR-451  and  pGL4.10-miR-709-WT  for  mmu-miR-709,  respectively. 
The WT insert was used to generate the insert with deletion of E-box motif 
by PCR-mediated site-directed mutagenesis/deletion using the following 
primer pairs: 5-AATGGTACCTAGGCTGCTACCCTGATAGT-3 and 
5-CCAGCACACTGTGCCTCTTGTCTCTCCTTCT-3, 5-AGAAG-
GAGAGACAAGAGGCACAGTGTGCTGG-3 and 5-ATGCTAGC-
TAAGATGGAGCTCTTGGTGTCCT-3,  5-AATGGTACCTAGGC-
TGCTACCCTGATAGT-3  and  5-ATGCTAGCTAAGATGGAGCT-
CTTGGTGTCCT-3 for miR-451 E-box-deletion mutant reporter con-
struct  (pGL4.10-miR-451-dE-box)  and  5-ATGGTACCAATCTTC-
ATTCGGGTGGCCATGAGTT-3 and 5-TGCTGCGGCAGGAGT-
GGGGGCAGCAT-3,  5-ATGCTGCCCCCACTCCTGCCGCAGCA-3   
and 5-AATGCTAGCCATTCTGTGGATCCTGAC-3, and 5-ATGG-
TACCAATCTTCATTCGGGTGGCCATGAGTT-3 and 5-AATGC-
TAGCCATTCTGTGGATCCTGAC-3 for miR-709 E-box-deletion 
mutant reporter construct (pGL4.10-miR-709-dE-box). NIH3T3 cells were 
transfected in 12-well plates using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s protocol. In brief, 2 µg of E47-pcDNA3 (Nie   
et al., 2003; provided by X.-H. Sun, Oklahoma Medical Research Founda-
tion) was co-transfected with 1 µg of the firefly luciferase construct contain-
ing a WT or a deleted E-box motif and 0.1 µg of the control reporter vector 
pRL-TK containing Renilla luciferase (Promega). Firefly and Renilla luciferase 
activities were measured consecutively using the dual luciferase assay (Pro-
mega) 24 h after transfection according to the manufacturer’s instructions. 
Firefly luciferase activity was normalized to Renilla luciferase activity.
Transfection of miRNA mimics
ICN1-overexpressing T-ALL  cells  were  isolated  and  transfected  with 
mmu-miR-451 mimic, mmu-miR-709 mimic or control miRNA mimic 
(Thermo Fisher Scientific) with Cy3-labeled oligonucleotides (1:3 relative 
amount of miRNA mimics) at a final concentration of 100 nM by Lipo-
fectamine 2000 (Invitrogen).
Quantitative analysis of miRNA expression
For analysis of miRNA expression in normal thymocytes, total RNA was 
extracted  using  the TRIzol  reagent  (Invitrogen). TaqMan  miRNA  assays 
(Applied Biosystems) were used to measure miR-451 and miR-709 expres-
sion in various T cell subsets and transduced ICN1 tumor cells. U6 snRNA 
was used as an internal control to normalize expression. Specific stem-loop 
miRNA primers for reverse transcription and TaqMan probes for miR451, 
miR-709, and U6 snRNA were purchased from ABI. For analysis of miRNA 
expression in ICN1-transformed tumor cells, total RNA was extracted using 
TRIzol reagent (Invitrogen) and was reverse transcribed to cDNA using 
miScript Reverse Transcription kit (QIAGEN). To quantify the miRNA levels, 
the ABI7300 real time PCR system (Applied Biosystems) was used in con-
junction with miScript SYBR Green PCR kit (QIAGEN) for mmu-miR-451, 
mmu-miR-709, mouse RNU6B, hsa-miR-451, and human RNU1A. RNU6B 
or RNU1A was used as an endogenous control to normalize expression. 
Specific primers for mmu-miR-451, mmu-miR-709, mouse RNU6B, 
hsa-miR-451, and human RNU1A were purchased from QIAGEN.
Quantitative RT-PCR analysis of protein-coding genes
cDNA was prepared by the oligo-dT primer method using the Super-
script II Reverse Transcription kit (Invitrogen). Quantitative RT-PCR 
was performed using an ABI7300 machine (Applied Biosystems). Mouse 
Myc, Akt, and Ras-GRF1 mRNA were determined relative to GAPDH 
expression using the TaqMan Gene Expression Assay (Applied Biosystems). 
Human MYC mRNAs was determined relative to GAPDH expression 
using  SYBR  Green  (Applied  Biosystems)  and  the  following  primers: 
MYC forward, 5-CTCTCCGTCCTCGGATTCT-3, MYC reverse, 
5-CAACATCGATTTCTTCCTCATC-3, GAPDH forward, 5-CTC-
CTCTGACTTCAACAGCGACAC-3,  GAPDH  reverse,  5-TGCTG-
TAGCCAAATTCGTTGTCAT-3.
ChIP assay
ChIP analysis was performed on mouse normal thymocytes according to the 
manufacturer’s protocol (ChIP-IT Express protocol; Active Motif). In brief, 
cells were cross-linked with 1% formaldehyde for 5 min at room temperature, JEM VOL. 208, April 11, 2011 
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and the reaction was stopped by the addition of 1x Glycine. Cells were lysed 
in ChIP lysis buffer, and then sonicated to shear chromatin into 200–1,000-
bp fragments. Chromatin was immunoprecipitated with anti-E2A polyclonal 
antibody (Santa Cruz Biotechnology, Inc.) or with normal rabbit IgG anti-
body (Santa Cruz Biotechnology, Inc.) incubated with protein G magnetic 
beads. After immunoprecipitation, cross-linking was reversed, the proteins 
were removed by treatment with Proteinase K, and DNA was recovered. 
DNA was purified by phenol/chloroform extraction and ethanol precipita-
tion. PCR was performed for miRNA promoter regions encompassing pu-
tative E2A binding motifs. PCR products were quantified by using SYBR 
green dye on an ABI 7300 real-time PCR machine. Fold enrichment was 
determined by performing a standard curve of input DNA. Primers used 
for the amplicon containing the two distal E box binding sites on the mmu-
miR-451 enhancer were: forward, 5-TAATGAGGCAAAGAGAAGG-
AGAGAC-3;  reverse,  5-ACAGCTCACTACATCCAGCTCTGTGA-3. 
Primers used for the amplicon containing the two E-box binding sites on the 
mmu-miR-709 enhancer were: forward, 5-AGCAGCAGCCGCTCCAT-
TACGA-3; reverse, 5-AACACTAGCACCTGGGGCATTCT-3. Control 
primers  for  the  nonbinding  site  were:  forward,  5-AAGGGTGGAGC-
CAAAGGGTCA-3; reverse, 5-TGGTGCAGGATGCATTGCTGAC-3.
Western blotting
T-ALL cells infected with either retroviral vector control, or retroviruses ex-
pressing the miR-451 mimic, the miR-709 mimic, or the miR-451 and 
miR-709 mimics in tandem were lysed in radioimmunoprecipitation assay 
buffer supplemented with Protease Inhibitor Cocktail (Sigma-Aldrich).   
Lysates (12 µg) were separated on 4–20% SDS-PAGE and transferred onto 
PVDF membrane (Millipore). Nonspecific binding was blocked by incuba-
tion in blocking buffer (5% nonfat milk in TBST), followed by incubation 
with the primary antibodies against Myc (Abcam), Akt, Ras-GRF1, E47 
(BD), or -actin (Sigma-Aldrich) and the appropriate horseradish peroxi-
dase–conjugated secondary antibodies diluted in blocking buffer. Immuno-
reactive proteins were detected using enhanced chemiluminescence reagents 
(GE Healthcare).
Cell viability assays
DsRed-ICN1 tumor cells were transduced by retroviral infection of MSCV-
IRES-GFP-MmE47 construct or MSCV-IRES-GFP empty vector as con-
trol. GFP+/DsRed+ cells were sorted and seeded into 96-well plates at a 
density of 4 × 103 cells/well and incubated for 5 d. Cell viability assay was 
determined on days 1, 3, and 5 of incubation by CellTiter-Glo luminescent 
reagent (Promega).
Tumor formation assays
4–5-wk-old Nude mice (Nu/Nu, Taconic) were adoptively transferred with 
T-ALL cells infected with retroviruses expressing nothing (vector control) or 
expressing miR-451, miR-709, or both miR-451 and miR-709 in tandem. 
Approximately 3 × 105 cells were intraperitoneally injected into Nu/Nu 
mice and tumor formation was monitored.
Histopathology
Tissue samples were fixed in 10% formalin solution (Sigma-Aldrich). Hema-
toxylin and eosin staining of various tissues, May Grunwald-Giemsa staining 
of blood smear and immunohistochemistry analysis using anti-CD4, -CD8, 
and -Ki67 antibodies were conducted in the Hematopathology Core facility 
of Dana-Farber/Harvard Cancer Center Research Pathology Core using 
standard staining procedures.
Primary human T-ALL samples and cell lines
T-ALL diagnostic specimens were collected with informed consent and Insti-
tutional Review Board approval from 10 patients treated in Dana-Farber Cancer 
Institute study 00–001 (Clinicaltrials.gov identifier: NCT00165178. http://
clinicaltrials.gov/ct2/show/NCT00165178?term=NCT00165178&rank=1.), 
as previously described (Gutierrez et al., 2009). All samples were purified   
to >90% lymphoblasts by centrifugation with Ficoll-Hypaque (Roche). 
The detailed information for each primary sample is described in Table S1. 
Thymocytes were obtained with informed consent and Institutional Review 
Board approval from normal thymic tissue removed at the time of cardiac 
surgery at the Children’s Hospital Boston (Boston, MA). 11 human T-ALL 
cell lines (DU528, JURKAT, PEER, DND-41, HPB-ALL, KOPT-K1, MOLT-4, 
PF-382, SUP-T7, CCRF-CEM, and RPMI-8402) were used in this study. 
Sequencing of exons 28, 29, and 34 of the human NOTCH1 gene, and exons 
9 and 10 of the human FBXW7 gene, was performed on human T-ALL pri-
mary samples at Beckman Coulter. RNA was extracted using TRIzol reagent 
according to the manufacturer’s instructions (Invitrogen).
Overexpression of miR-451 and GsI treatment of human  
T-ALL cell lines
Retroviruses encoding EGFP and miR-451 or no miRNA were produced 
by 293T cells co-transfected with the CMMP retroviral construct, a pack-
aging plasmid gag-pol, and an envelope plasmid VSV-G. 4 human T-ALL cell 
lines (JURKAT, RPMI-8402, HPB-ALL, and KOPT-K1) were infected with 
retroviruses in the presence of polybrene by centrifugation at 2,500 rpm for 
1.5 h. EGFP-positive cells were sorted by flow cytometry. For RNA analysis, 
the cells were treated with DMSO or MRK-003 GSI (provided by Merck 
Research Laboratory) for 3 d. For cell viability analysis, the cells were treated 
with DMSO or GSI for 5 d in 96-well plates and cell viability was measured 
by CellTiter-Glo (Promega).
Online supplemental material
Fig. S1 shows dynamic regulation of miR-451 and miR-709 expressions 
during normal thymocyte development and correlation of miR-451 expression 
with GFP expression in cells infected with the GFP-miR-451–expressing 
vector. Fig. S2 demonstrates that reconstitution of miR-451 and miR-709 by 
transfection represses T-ALL tumor formation in vivo. Fig. S3 indicates that 
coordinate expression of miR-451 and miR-709 blocks ICN1-induced tumor 
initiation in vivo. Fig. S4 shows that expression of miR-451 and miR-709 
in BM cells does not block the generation of extrathymic, nontumorigenic, 
CD4+CD8+ cells during the early stages after BM transplantation. Fig. S5 
shows overexpression of miR-451 in human T-ALL cell lines. Table S1 shows 
the genetic status of NOTCH1 and FBXW7 genes and expressions of cell sur-
face markers in primary T-ALL and cell lines. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20102384/DC1.
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